Tempest Therapeutics Inc
TPST3.120USD
+0.140+4.70%
收盤 12/19, 16:00（美東）報價延遲15分鐘
13.85M總市值
虧損本益比TTM
關於 Tempest Therapeutics Inc 公司
Tempest Therapeutics, Inc. is a clinical-stage biotechnology company advancing a diverse portfolio of small molecule product candidates containing tumor-targeted and/or immune-mediated mechanisms with the potential to treat a range of tumors. Its two clinical-stage therapeutic product candidates are Amezalpat and TPST-1495. Amezalpat is an oral, small molecule, selective antagonist of peroxisome proliferator-activated receptor alpha. The ongoing global randomized Phase Ib/II trial of Amezalpat combined with the standard-of-care first-line regimen of atezolizumab and bevacizumab in patients with advanced or metastatic hepatocellular carcinoma. The Company’s second clinical program, TPST-1495, a dual antagonist of the EP2 and EP4 receptors of prostaglandin E2, a pathway implicated in multiple cancers.
Tempest Therapeutics Inc簡介
公司代碼TPST
公司名稱Tempest Therapeutics Inc
上市日期Oct 04, 2012
CEO- -
員工數量24
證券類型Ordinary Share
年結日Oct 04
公司地址2000 Sierra Point Parkway
城市BRISBANE
上市交易所NASDAQ OMX - NASDAQ BASIC
國家United States of America
郵編94005
電話14157988589
網址https://www.tempesttx.com/
公司代碼TPST
上市日期Oct 04, 2012
CEO- -
Tempest Therapeutics Inc公司高管
名稱
名稱/職務
職務
持股
持股變動
Mr. Stephen R. Brady
Mr. Stephen R. Brady
President, Principal Executive Officer, Director
President, Principal Executive Officer, Director
3.61K
+1.29%
Mr. Nicholas Maestas
Mr. Nicholas Maestas
Principal Financial Officer
Principal Financial Officer
666.00
-0.15%
Mr. Michael (Mike) Raab
Mr. Michael (Mike) Raab
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Geoffrey M. (Geoff) Nichol
Dr. Geoffrey M. (Geoff) Nichol
Independent Director
Independent Director
--
--
Ms. Christine A. Pellizzari, J.D.
Ms. Christine A. Pellizzari, J.D.
Independent Director
Independent Director
--
--
Dr. Ronit Simantov, M.D.
Dr. Ronit Simantov, M.D.
Independent Director
Independent Director
--
--
名稱
名稱/職務
職務
持股
持股變動
Mr. Stephen R. Brady
Mr. Stephen R. Brady
President, Principal Executive Officer, Director
President, Principal Executive Officer, Director
3.61K
+1.29%
Mr. Nicholas Maestas
Mr. Nicholas Maestas
Principal Financial Officer
Principal Financial Officer
666.00
-0.15%
Mr. Michael (Mike) Raab
Mr. Michael (Mike) Raab
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Geoffrey M. (Geoff) Nichol
Dr. Geoffrey M. (Geoff) Nichol
Independent Director
Independent Director
--
--
Ms. Christine A. Pellizzari, J.D.
Ms. Christine A. Pellizzari, J.D.
Independent Director
Independent Director
--
--
Dr. Ronit Simantov, M.D.
Dr. Ronit Simantov, M.D.
Independent Director
Independent Director
--
--
收入明細
由於公司未披露，未能獲取相關數據
由於公司未披露，未能獲取相關數據
業務
地區
由於公司未披露，未能獲取相關數據
股東統計
更新時間: 12月6日 週六
更新時間: 12月6日 週六
持股股東
股東類型
持股股東
持股股東
佔比
Versant Ventures
5.48%
The Vanguard Group, Inc.
3.30%
Geode Capital Management, L.L.C.
0.83%
BlackRock Institutional Trust Company, N.A.
0.79%
Fidelity Management & Research Company LLC
0.67%
其他
88.93%
持股股東
持股股東
佔比
Versant Ventures
5.48%
The Vanguard Group, Inc.
3.30%
Geode Capital Management, L.L.C.
0.83%
BlackRock Institutional Trust Company, N.A.
0.79%
Fidelity Management & Research Company LLC
0.67%
其他
88.93%
股東類型
持股股東
佔比
Venture Capital
5.48%
Investment Advisor
5.46%
Investment Advisor/Hedge Fund
0.87%
Research Firm
0.12%
Individual Investor
0.11%
其他
87.97%
機構持股
更新時間: 10月1日 週三
更新時間: 10月1日 週三
報告期間
機構數
持股數
持股佔比
持股變動
2025Q3
71
871.05K
19.62%
-32.43K
2025Q2
71
462.14K
11.78%
-326.50K
2025Q1
72
466.15K
11.99%
-315.34K
2024Q4
74
6.85M
15.70%
-2.07M
2024Q3
64
6.40M
25.40%
-2.51M
2024Q2
60
6.46M
29.08%
-2.26M
2024Q1
57
6.17M
27.79%
-2.56M
2023Q4
58
6.52M
33.89%
-1.52M
2023Q3
54
8.53M
66.99%
-219.33K
2023Q2
55
8.95M
101.95%
+3.83M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Versant Ventures
162.97K
3.67%
-106.80K
-39.59%
Aug 11, 2025
The Vanguard Group, Inc.
134.61K
3.03%
+111.69K
+487.45%
Jun 30, 2025
Geode Capital Management, L.L.C.
34.74K
0.78%
+1.40K
+4.21%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
39.07K
0.88%
-3.84K
-8.95%
Jun 30, 2025
Fidelity Management & Research Company LLC
33.23K
0.75%
-1.00
-0.00%
Jun 30, 2025
UBS Financial Services, Inc.
11.22K
0.25%
-13.68K
-54.93%
Jun 30, 2025
Brady (Stephen R)
3.61K
0.08%
+46.00
+1.29%
Apr 09, 2025
Morgan Stanley Smith Barney LLC
2.11K
0.05%
+49.00
+2.38%
Jun 30, 2025
查看更多
持股ETF
更新時間: 12月2日 週二
更新時間: 12月2日 週二
機構名稱
佔比
iShares Micro-Cap ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Micro-Cap ETF
佔比0%
iShares Core S&P Total U.S. Stock Market ETF
佔比0%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
Apr 07, 2025
Merger
13→1
Jun 25, 2021
Merger
15→1
Jun 25, 2021
Merger
15→1
Jun 25, 2021
Merger
15→1
Jun 25, 2021
Merger
15→1
公告日期
類型
比率
Apr 07, 2025
Merger
13→1
Jun 25, 2021
Merger
15→1
Jun 25, 2021
Merger
15→1
Jun 25, 2021
Merger
15→1
Jun 25, 2021
Merger
15→1
常見問題
Tempest Therapeutics Inc的前五大股東是誰？
Tempest Therapeutics Inc的前五大股東如下：
Versant Ventures持有股份：162.97K佔總股份比例：3.67%。
The Vanguard Group, Inc.持有股份：134.61K佔總股份比例：3.03%。
Geode Capital Management, L.L.C.持有股份：34.74K佔總股份比例：0.78%。
BlackRock Institutional Trust Company, N.A.持有股份：39.07K佔總股份比例：0.88%。
Fidelity Management & Research Company LLC持有股份：33.23K佔總股份比例：0.75%。
Versant Ventures持有股份：162.97K佔總股份比例：3.67%。
The Vanguard Group, Inc.持有股份：134.61K佔總股份比例：3.03%。
Geode Capital Management, L.L.C.持有股份：34.74K佔總股份比例：0.78%。
BlackRock Institutional Trust Company, N.A.持有股份：39.07K佔總股份比例：0.88%。
Fidelity Management & Research Company LLC持有股份：33.23K佔總股份比例：0.75%。
Tempest Therapeutics Inc的前三大股東類型是什麼？
Tempest Therapeutics Inc 的前三大股東類型分別是：
Versant Ventures
The Vanguard Group, Inc.
Geode Capital Management, L.L.C.
Versant Ventures
The Vanguard Group, Inc.
Geode Capital Management, L.L.C.
有多少機構持有Tempest Therapeutics Inc(TPST)的股份？
截至2025Q3，共有71家機構持有Tempest Therapeutics Inc的股份，合計持有的股份價值約為871.05K，占公司總股份的19.62% 。與2025Q2相比，機構持股有所增加，增幅為7.84%。
哪個業務部門對Tempest Therapeutics Inc的收入貢獻最大？
在--，--業務部門對Tempest Therapeutics Inc的收入貢獻最大，創收--，占總收入的--% 。
